For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
67
views
0
references
 Top references
cited by
113
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      12
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: not found

      Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial.

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Chikungunya is an emerging arthropod-borne disease that has spread from tropical endemic areas to more temperate climates of the USA and Europe. However, no specific treatment or preventive measure is yet available. We aimed to investigate the immunogenicity and safety of a live recombinant measles-virus-based chikungunya vaccine.

          Related collections

          Author and article information

          Journal
          Journal ID (iso-abbrev): Lancet Infect Dis
          Title: The Lancet. Infectious diseases
          ISSN (Electronic): 1474-4457
          ISSN (Print): 1473-3099
          Publication date (Electronic): May 2015
          Volume: 15
          Issue: 5
          Affiliations
          [1 ] Themis Bioscience GmbH, Vienna, Austria.
          [2 ] Department of Clinical Pharmacology, Medical University of Vienna, Austria, Europe.
          [3 ] Walter Reed Army Institute of Research, Viral Diseases Branch, Silver Springs, MD, USA.
          [4 ] Department of Infections and Epidemiology, Institut Pasteur, La Réunion, UMR U1187 PIMIT (I2T), France.
          [5 ] Department of Clinical Pharmacology, Medical University of Vienna, Austria, Europe. Electronic address: bernd.jilma@meduniwien.ac.at.
          [6 ] Viral Genomics and Vaccination Unit, Institut Pasteur, Paris, CNRS UMR-3569, France.
          Article
          Publisher Item ID: S1473-3099(15)70043-5
          DOI: 10.1016/S1473-3099(15)70043-5
          PubMed ID: 25739878
          SO-VID: b2541345-bf5c-412a-88b1-4a1cd2a395a6
          Copyright © Copyright © 2015 Elsevier Ltd. All rights reserved.
          History

          Data availability:

          Comments

          Comment on this article

          scite_

          Similar content12

          See all similar

          Cited by111

          See all cited by